EpiVax is a biotechnology company specializing in the discovery and development of vaccines and immunotherapies. The company operates in the healthcare and biotechnology markets, focusing on creating solutions that enhance human health. EpiVax serves a diverse range of clients, including pharmaceutical companies, research institutions, and healthcare organizations. The business model revolves around leveraging proprietary computational tools and platforms to design and optimize vaccines and therapeutic proteins. Revenue is generated through partnerships, collaborations, and licensing agreements with other entities in the healthcare sector. EpiVax has been particularly active in the development of a COVID-19 vaccine, partnering with various organizations to accelerate vaccine development and make it accessible to developing countries. The company is headquartered in Providence, RI, and is led by CEO and CSO Dr. Anne S. De Groot.

Keywords: biotechnology, vaccines, immunotherapies, COVID-19, healthcare, computational tools, partnerships, licensing, global health, Providence